Statistics for A phase II trial of UGT1A1 genotype-guided FOLFIRI plus bevacizumab as first-line therapy for advanced, unresectable colorectal cancer
Total visits
| views | |
|---|---|
| A phase II trial of UGT1A1 genotype-guided FOLFIRI plus bevacizumab as first-line therapy for advanced, unresectable colorectal cancer | 0 |
Total visits per month
| views | |
|---|---|
| October 2024 | 0 |
| November 2024 | 0 |
| December 2024 | 0 |
| January 2025 | 0 |
| February 2025 | 0 |
| March 2025 | 0 |
| April 2025 | 0 |
File Visits
| views | |
|---|---|
| java.util.UUID:b2464c48-eb8b-4bbe-9d80-af9c4106815e | 14 |
| java.util.UUID:9bd8dfae-de83-43ee-96a6-5facd64e4322 | 5 |
| Sanoff2024Phase-CCBYNC.pdf | 2 |
| java.util.UUID:5d4b5cd9-0c29-4e4d-a9e9-4b6f5f649c74 | 1 |